Skip to content

MDMA does not alter responses to the Trier Social Stress Test in humans

Anya K. Bershad, Melissa A. Miller, Harriet de Wit

Psychopharmacology July 1, 2017 DOI: 10.1007/s00213-017-4621-x (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 39
Population Healthy adults
Intervention MDMA
Dose 0.5 mg/kg, 1.0 mg/kg
Topics Anxiety MDMA
Keywords Stress Cortisol
Citations 12
Key findings MDMA did not reduce subjective or objective responses to acute psychosocial stress in healthy adults.

Abstract

Rationale ±3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) is a stimulant-psychedelic drug with unique social effects. It may dampen reactivity to negative social stimuli such as social threat and rejection. Perhaps because of these effects, MDMA has shown promise as a treatment for post-traumatic stress disorder (PTSD). However, the effect of single doses of MDMA on responses to an acute psychosocial stressor has not been tested.

Objectives: In this study, we sought to test the effects of MDMA on responses to stress in healthy adults using a public speaking task. We hypothesized that the drug would reduce responses to the stressful task.

Methods: Volunteers ( N = 39) were randomly assigned to receive placebo ( N = 13), 0.5 mg/kg MDMA ( N = 13), or 1.0 mg/kg MDMA ( N = 13) during a stress and a no-stress session. Dependent measures included subjective reports of drug effects and emotional responses to the task, as well as salivary cortisol, heart rate, and blood pressure.

Results: The stress task produced its expected increase in physiological responses (cortisol, heart rate) and subjective ratings of stress in all three groups, and MDMA produced its expected subjective and physiological effects. MDMA alone increased ratings of subjective stress, heart rate, and saliva cortisol concentrations, but contrary to our hypothesis, it did not moderate responses to the Trier Social Stress Test.

Conclusions: Despite its efficacy in PTSD and anxiety, MDMA did not reduce either the subjective or objective responses to stress in this controlled study. The conditions under which MDMA relieves responses to negative events or memories remain to be determined.

Comparable studies

Other randomized controlled trials on MDMA for anxiety, most cited first.

Study Year Design Participants
Gender differences in the subjective effects of MDMA Healthy volunteers with no or minimal MDMA experience 2001 Pooled analysis of three double-blind placebo-controlled studies n = 74
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Autistic adults with marked to very severe social anxiety 2018 Randomized controlled trial n = 12
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study People with life-threatening illnesses and anxiety 2020 Randomized controlled trial n = 18
A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults Healthy adults aged 21–55 from a major metropolitan area 2022 Randomized controlled trial n = 34
Effects of MDMA-assisted therapy for PTSD on self-experience Participants with severe PTSD 2024 Randomized controlled trial n = 90

Explore topics

By condition and practice